Adverts

Open Access Articles- Top Results for Selepressin

Selepressin

</th></tr>
Selepressin
Systematic (IUPAC) name
1-({(4R,7S,10S,13S,16S,19R)-19-Amino-10-(4-amino-4-oxobutyl)-7-(2-amino-2-oxoethyl)-16-benzyl-13-[(2S)-2-butanyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl}carbonyl)-L-prolyl-N5-isopropyl-L-ornithylglycinamide
Clinical data
Identifiers
876296-47-8
None
PubChem CID 53330936
ChemSpider 26609297
Chemical data
Formula C46H73N13O11S2
1048.282 g/mol

Selepressin (INN) (code name FE-202158), also known as [Phe(2),Ile(3), Hgn(4),Orn(iPr)(8)]vasopressin) is a potent, highly selective, short-acting peptide full agonist of the vasopressin 1A receptor and analog of vasopressin which is under development by Ferring Pharmaceuticals for the treatment of vasodilatory hypotension in septic shock.[1][2][3][4]

References

  1. Jeremy I Levin (24 October 2014). Macrocycles in Drug Discovery. Royal Society of Chemistry. pp. 313–. ISBN 978-1-84973-701-2. 
  2. Jean-Louis Vincent (23 September 2012). Annual Update in Intensive Care and Emergency Medicine 2012. Springer Science & Business Media. pp. 80–. ISBN 978-3-642-25716-2. 
  3. J. L. Vincent (2 September 2008). Yearbook of Intensive Care and Emergency Medicine 2008. Springer Science & Business Media. pp. 427–. ISBN 978-3-540-77290-3. 
  4. Laporte, R.; Kohan, A.; Heitzmann, J.; Wisniewska, H.; Toy, J.; La, E.; Tariga, H.; Alagarsamy, S.; Ly, B.; Dykert, J.; Qi, S.; Wisniewski, K.; Galyean, R.; Croston, G.; Schteingart, C. D.; Riviere, P. J.- M. (2011). "Pharmacological Characterization of FE 202158, a Novel, Potent, Selective, and Short-Acting Peptidic Vasopressin V1a Receptor Full Agonist for the Treatment of Vasodilatory Hypotension". Journal of Pharmacology and Experimental Therapeutics 337 (3): 786–796. ISSN 0022-3565. doi:10.1124/jpet.111.178848. 



Lua error in package.lua at line 80: module 'Module:Buffer' not found.